Company / Capital Expenditures
Adaptimmune Therapeutics PLC Capital Expenditures History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$886.0K
FY2024
5-year range
$886.0K / $29.5M
FY2020-FY2024
Trend
-81.1%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures has fluctuated over the past 9 years, ranging from $886,000 in FY2024 to $29M in FY2022.
Based on SEC 10-K filings.
$886,000 in FY2024 with a 5-year CAGR of -11.1%.
Declined from $29M to $886,000 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -53.1%
- 5-Year CAGR
- -11.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -11.1%, indicating a declining trend.
- In FY2024, capital expenditures decreased 81.1% year-over-year.
- Peak capital expenditures was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -3.53 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $886.0K | -81.1% |
| FY2023 | $4.7M | -84.1% |
| FY2022 | $29.5M | +244.0% |
| FY2021 | $8.6M | +266.3% |
| FY2020 | $2.3M | +47.0% |
| FY2019 | $1.6M | -59.3% |
| FY2018 | $3.9M | -84.1% |
| FY2017 | $24.6M | +114.2% |
| FY2016 | $11.5M | - |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026